Evaluation of VCAM-1 antibodies as therapeutic agent for atherosclerosis in apolipoprotein E-deficient mice
JG Park, SY Ryu, IH Jung, YH Lee, KJ Kang, MR Lee… - Atherosclerosis, 2013 - Elsevier
OBJECTIVE: Blocking agents targeting cell adhesion molecules have been developed to
prevent cardiovascular diseases such as atherosclerosis, whereas relatively little attention
has been paid to the therapeutic potential of vascular cell adhesion molecule (VCAM)-1 as
an inflammatory disease target. Two novel, fully human antibodies, H6 and 7H, against
human VCAM-1 (hVCAM-1) were developed and tested to validate the hypothesis that
blocking VCAM-1 ameliorates atherosclerosis in apolipoprotein E-deficient (ApoE−/−) mice …
prevent cardiovascular diseases such as atherosclerosis, whereas relatively little attention
has been paid to the therapeutic potential of vascular cell adhesion molecule (VCAM)-1 as
an inflammatory disease target. Two novel, fully human antibodies, H6 and 7H, against
human VCAM-1 (hVCAM-1) were developed and tested to validate the hypothesis that
blocking VCAM-1 ameliorates atherosclerosis in apolipoprotein E-deficient (ApoE−/−) mice …
